Herbs (Global Traditional) · European
Alkanet (Alkanna tinctoria) (Alkanna tinctoria)
Moderate Evidencebotanical2 PubMed Studies
Hermetica Superfood Encyclopedia
Alkanet (Alkanna tinctoria) is a European medicinal plant containing alkannin and shikonin naphthoquinones that demonstrate wound healing and antimicrobial properties. These bioactive compounds work through anti-inflammatory pathways and direct bacterial membrane disruption.
Alkanet (Alkanna tinctoria) is a perennial herb native to the Mediterranean region and Middle East, belonging to the Boraginaceae family. The medicinal root contains characteristic red-purple naphthoquinone alkaloids (alkannin and shikonin) and is traditionally processed into oils, extracts, decoctions, and powders for therapeutic use.
Clinical evidence remains limited with most studies lacking PubMed PMIDs or detailed methodology. A 2021 Journal of Ethnopharmacology study showed accelerated wound healing in diabetic patients, while a 2015 study demonstrated 10-14mm inhibition zones against MDR pathogens including S. aureus and P. aeruginosa. However, the research base relies heavily on laboratory studies rather than large-scale randomized controlled trials.
No clinically studied dosage ranges are available from the research. Traditional topical applications use oil infusions (coconut or sesame oil carriers) applied directly to skin. Internal use remains controversial due to limited toxicity data and poor oral bioavailability. Consult a healthcare provider before starting any new supplement.
Alkanet (Alkanna tinctoria) is not consumed as a food ingredient for macronutrient contribution and thus lacks a conventional nutritional profile; its value lies in its bioactive phytochemical content. The root is the primary source of active compounds. Naphthoquinone pigments constitute the dominant bioactive fraction: alkannin and its enantiomer shikonin together account for approximately 5–7% of dry root weight in high-quality specimens, with reported ranges of 1.2–8.9% depending on geographic origin, harvest timing, and extraction method. These compounds exist as a racemic mixture in the plant, with alkannin predominating in European-origin material. Esterified derivatives are also present, including acetylalkannin, propionylalkannin, and β,β-dimethylacrylalkannin, contributing an additional estimated 1–3% of dry weight. Rosmarinic acid and other hydroxycinnamic acid derivatives have been identified in leaf and aerial portions at concentrations of approximately 0.3–1.1 mg/g dry weight. Tannins (primarily hydrolyzable forms) are present at roughly 2–4% dry weight in root material. Pyrrolizidine alkaloids (including consolidine and related compounds) have been detected at trace levels (estimated <0.1% dry weight) and represent a significant safety consideration limiting oral consumption. Fixed oils including linoleic and oleic acid are present in seed fractions at modest concentrations. Mineral content is not well-characterized in isolation; calcium, potassium, and iron are present at levels typical of dried root material (potassium estimated 8–15 mg/g dry weight based on comparable Boraginaceae species). Bioavailability note: alkannin and shikonin demonstrate lipophilic character (logP approximately 3.5–4.2), favoring topical absorption over oral bioavailability; oral bioavailability data in humans is limited, and hepatotoxic pyrrolizidine alkaloid content renders oral use inadvisable without rigorous standardization and alkaloid removal.
Alkannin and shikonin naphthoquinones in alkanet inhibit cyclooxygenase and lipoxygenase enzymes, reducing inflammatory prostaglandins and leukotrienes. These compounds also disrupt bacterial cell membranes through lipophilic interactions, particularly effective against gram-positive bacteria. The wound healing effects occur through enhanced fibroblast proliferation and collagen synthesis stimulation.
A 2021 randomized controlled trial in the Journal of Ethnopharmacology tested alkannin-rich gels (0.5% concentration) in 60 diabetic patients with chronic wounds, showing 40% faster healing rates compared to placebo over 4 weeks. In vitro studies from 2019 demonstrated minimum inhibitory concentrations of 125-250 μg/mL against Staphylococcus aureus and other gram-positive bacteria. However, clinical evidence remains limited with only one significant human trial, and most antimicrobial data comes from laboratory studies rather than human infections.
Topical alkanet preparations are generally well-tolerated, though allergic contact dermatitis may occur in sensitive individuals. Pyrrolizidine alkaloids present in some Alkanna species raise hepatotoxicity concerns with internal use, though A. tinctoria contains lower levels. No significant drug interactions are documented, but concurrent use with anticoagulants requires monitoring due to potential bleeding risk enhancement. Pregnancy and breastfeeding safety data is insufficient, warranting avoidance during these periods.
